Association of XRCC3, XRCC4, BAX, and BCL-2 Polymorphisms with the Risk of Breast Cancer

Overview

Journal Int J Breast Cancer

Publisher Wiley

Date 2022 Mar 24

PMID 35320970

Authors

Emre Ozoran

Fadime Didem Can Trabulus

Duygu Erhan

Bahadir Batar

Mehmet Guven

Affiliations

Soon will be listed here.

Abstract

Background: Breast cancer is the most common malignancy in women. Genetic risk factors associated with breast cancer incidence have been identified.

Aims: This study is aimed at determining the association of XRCC3 Thr241Met (rs861539), XRCC4 G(-1394) T (rs6869366) DNA repair and BAX G(-248) A (rs4645878), and BCL2 C(-938) A (rs2279115) apoptotic gene polymorphisms with breast cancer.

Materials And Methods: Genetic analysis was performed using peripheral blood samples. Gene polymorphisms were detected by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. 175 patients and 158 healthy controls were enrolled in the study.

Results: Breast cancer risk was 5.43 times more in individuals with AA genotype of Bax G(-248) A (rs4645878) ( = 0.002). The risk of metastasis was 11 times with this genotype. It was associated with 6 times more risk of having a tumor larger than 2 cm. The risk of breast cancer was 2.77 times more in individuals carrying the Met/Met genotype of XRCC3 Thr241Met (rs861539) ( = 0.009). The risk of having advanced clinical stage (stage III+IV) with the Met/Met genotype was 4 times more increased. No relationship with breast cancer was found with XRCC4 G(-1394) T (rs6869366) and BCL2 C(-938) A (rs2279115) gene polymorphisms.

Conclusion: Multicenter trials using subjects with genetic variations are needed to establish the relationship between breast cancer and single gene polymorphism.

Citing Articles

Genetic variants of the DNA repair gene: risk implications in breast cancer among Iraqi patients.

Al-Khalidi Z, Al-Husseini R Prz Menopauzalny. 2025; 23(4):173-179.

PMID: 39811388 PMC: 11726187. DOI: 10.5114/pm.2024.145948.

A systematic review of candidate genes and their relevant pathways for metastasis among adults diagnosed with breast cancer.

Gehling G, Alfaqih M, Pruinelli L, Starkweather A, Dungan J Breast Cancer Res. 2024; 26(1):165.

PMID: 39593069 PMC: 11590482. DOI: 10.1186/s13058-024-01914-6.

Analysis of the Polymorphisms and Expression Levels of the BCL2, BAX and c-MYC Genes in Patients with Ovarian Cancer.

Olbromski P, Bogacz A, Bukowska M, Kaminski A, Moszynski R, Pawlik P Int J Mol Sci. 2023; 24(22).

PMID: 38003498 PMC: 10671037. DOI: 10.3390/ijms242216309.

References

Wang X, Lin Y, Lan F, Yu Y, Ouyang X, Liu W . BAX and CDKN1A polymorphisms correlated with clinical outcomes of gastric cancer patients treated with postoperative chemotherapy. Med Oncol. 2014; 31(11):249. DOI: 10.1007/s12032-014-0249-4. View

Ji W, He N . Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma. Int J Clin Exp Pathol. 2015; 8(1):894-9. PMC: 4348835. View

Thacker J . The RAD51 gene family, genetic instability and cancer. Cancer Lett. 2005; 219(2):125-35. DOI: 10.1016/j.canlet.2004.08.018. View

Perou C, Jeffrey S, van de Rijn M, Rees C, Eisen M, Ross D . Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A. 1999; 96(16):9212-7. PMC: 17759. DOI: 10.1073/pnas.96.16.9212. View

Gochhait S, Bukhari S, Bairwa N, Vadhera S, Darvishi K, Raish M . Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res. 2007; 9(5):R71. PMC: 2242669. DOI: 10.1186/bcr1780. View

Smith T, Miller M, Lohman K, Lange E, Case L, Mohrenweiser H . Polymorphisms of XRCC1 and XRCC3 genes and susceptibility to breast cancer. Cancer Lett. 2003; 190(2):183-90. DOI: 10.1016/s0304-3835(02)00595-5. View

Chai F, Liang Y, Chen L, Zhang F, Jiang J . Association between XRCC3 Thr241Met Polymorphism and Risk of Breast Cancer: Meta-Analysis of 23 Case-Control Studies. Med Sci Monit. 2015; 21:3231-40. PMC: 4627365. DOI: 10.12659/msm.894637. View

Kholoussi N, El-Nabi S, Esmaiel N, Abd El-Bary N, El-Kased A . Evaluation of Bax and Bak gene mutations and expression in breast cancer. Biomed Res Int. 2014; 2014:249372. PMC: 3933335. DOI: 10.1155/2014/249372. View

Gu S, Wu Q, Zhao X, Wu W, Gao Z, Tan X . Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non-small-cell lung carcinoma treated with platinum-based chemotherapy. Cancer Sci. 2012; 103(8):1451-9. PMC: 7659371. DOI: 10.1111/j.1349-7006.2012.02323.x. View

10.

Brown L, Berse B, Jackman R, Tognazzi K, Guidi A, Dvorak H . Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995; 26(1):86-91. DOI: 10.1016/0046-8177(95)90119-1. View

11.

Searle C, Brock I, Cross S, Balasubramanian S, Reed M, Cox A . A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients. Springerplus. 2013; 1:38. PMC: 3725909. DOI: 10.1186/2193-1801-1-38. View

12.

Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M . Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst. 1997; 89(2):139-47. DOI: 10.1093/jnci/89.2.139. View

13.

Chiu C, Wang H, Wang C, Wang C, Lin C, Shen C . A new single nucleotide polymorphism in XRCC4 gene is associated with breast cancer susceptibility in Taiwanese patients. Anticancer Res. 2008; 28(1A):267-70. View

14.

Zhou L, Luan H, Dong X, Jin G, Ma D, Shang H . Association of functional polymorphisms of the XRCC4 gene with the risk of breast cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012; 13(7):3431-6. DOI: 10.7314/apjcp.2012.13.7.3431. View

15.

Alam M, Kashyap T, Mishra P, Panda A, Nagini S, Mishra R . Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance. Head Neck. 2018; 41(1):185-197. DOI: 10.1002/hed.25471. View

16.

Xue R, Peng Y, Han B, Li X, Chen Y, Pei H . Metastasis suppressor NME1 promotes non-homologous end joining of DNA double-strand breaks. DNA Repair (Amst). 2019; 77:27-35. DOI: 10.1016/j.dnarep.2019.03.003. View

17.

Chen K, Hu Z, Wang L, Sturgis E, El-Naggar A, Zhang W . Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2007; 28(9):2008-12. DOI: 10.1093/carcin/bgm172. View

18.

Qureshi Z, Mahjabeen I, Baig R, Kayani M . Correlation between selected XRCC2, XRCC3 and RAD51 gene polymorphisms and primary breast cancer in women in Pakistan. Asian Pac J Cancer Prev. 2015; 15(23):10225-9. DOI: 10.7314/apjcp.2014.15.23.10225. View

19.

Jara L, Dubois K, Gaete D, de Mayo T, Ratkevicius N, Bravo T . Variants in DNA double-strand break repair genes and risk of familial breast cancer in a South American population. Breast Cancer Res Treat. 2010; 122(3):813-22. DOI: 10.1007/s10549-009-0709-2. View

20.

Zhang N, Li X, Tao K, Jiang L, Ma T, Yan S . BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet. 2011; 12:48. PMC: 3078853. DOI: 10.1186/1471-2350-12-48. View